Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek/General Mills

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences has entered into a 15-year DHA license and supply agreement with General Mills, the firm announces June 16. Under the terms of the agreement, the food company "may develop certain food products containing Martek DHA and must purchase, subject to certain exceptions, substantially all of its DHA needs from Martek for these products in the United States and other designated territories," the release states. Furthermore, General Mills products containing Martek DHA are required to bear the Martek DHA logo on the product labeling as well as related marketing, advertising and promotional materials. The initial launch of a General Mills/Martek DHA product is slated for 2007, according to Martek. General Mills owns a variety of cereal, snack and processed food brands, including Yoplait, Colombo, Bisquick, Nature Valley and Fruit Roll-Ups...

You may also be interested in...



Martek, General Mills seek shelf-stable DHA

The nutritional oils firm looks to expand the use of DHA in long shelf-life foods through a partnership with General Mills. "We do not have all product categories licked yet," such as dry cereal, said Martek Biosciences Chief Financial Officer Pete Buzy Sept. 21 at the UBS Global Life Science Conference in New York. The agreement signed in February gives Martek rights to use General Mills' technology in exchange for exclusive use by GM of Martek's DHA formula in some applications. The deal is separate from a 15-year DHA license and supply agreement the firms signed in 2006 (1"The Tan Sheet" June 19, 2006, In Brief). A spokeswoman said Martek expects to commercialize its DHA in long shelf-life foods by early 2011. The Columbia, Md.-based maker of life'sDHA projects the market for omega-3 fortified products will reach $8 billion by 2012

Martek partners with Hain

Martek will serve as the exclusive DHA and ARA supplier for all Hain Celestial infant formula products in the U.S., under a license and supply agreement announced Aug. 8. The companies also said they are discussing the potential expansion of their relationship into other food and beverage products. Martek's vegetarian source of omega-3 and omega-6 fatty acids will be included in Hain Celestial's infant formula Earth's Best at levels shown through research to optimize brain and eye development. Martek's blend of DHA and ARA is the only source of these fatty acid nutrients used in U.S. infant formula 1("The Tan Sheet" June 19, 2006, In Brief and 2"The Tan Sheet" Jan. 16, 2006, p. 12). Hain Celestial manufactures products under brands such as Rice Dream and WestSoy...

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel